Researchers examined the long-term safety of glucocorticoid use in patients with early rheumatoid arthritis, defined as disease duration <6 months, from the multicenter observational Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort.
EULAR has released new recommendations for rheumatoid arthritis management with disease-modifying antirheumatic drugs.
A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.
Study finds weak evidence for using biomarkers as a guide to tapering or discontinuing biologic therapy in patients with rheumatoid arthritis.
Regulator advises use of unique suffix system to identify each biological product and biosimilars.
Data from the Nurses’ Health Studies were analyzed to determine if there is a link between seropositive and seronegative rheumatoid arthritis and age of menopause onset.
Study examines the effect of TNFi therapy on inflammation and its ability to reduce the incidence of myocardial infarction.
EULAR revised its recommendations for management of early arthritis, including faster referral to specialists from onset of symptoms.
A phase 3 trial examined the superiority of sarilumab monotherapy compared with adalimumab monotherapy in patients who were either intolerant of or inappropriate candidates for methotrexate therapy.
